Taryn Youngstein1, Patrycja Hoffmann2, Ahmet Gül3, Thirusha Lane1, Rene Williams1, Dorota M Rowczenio1, Huri Ozdogan4, Serdal Ugurlu4, John Ryan5, Len Harty5, Sean Riminton6, Alex P Headley6, Joachim Roesler7, Norbert Blank8, Jasmin B Kuemmerle-Deschner9, Anna Simon10, Adrian S Woolf11, Philip N Hawkins1, Helen J Lachmann1. 1. National Amyloidosis Centre, University College London Medical School, London, UK. 2. National Human Genome Research Institute, National Institute of Health, Bethesda, MD, USA. 3. Division of Rheumatology, Istanbul Faculty of Medicine. 4. Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical School, Istanbul University, Istanbul, Turkey. 5. Department of Rheumatology, Cork University Hospital, Cork, Ireland. 6. Department of Immunology, Concord Hospital, Sydney, Australia. 7. Department of Paediatric Immunology, University Hospital Carl Gustav Carus, Dresden. 8. Division of Rheumatology, University of Heidelberg, Heidelberg. 9. Division of Pediatric Rheumatology, Department of Pediatrics, University Hospital Tuebingen, Germany. 10. General Internal Medicine, Raboud University, Nijmegen, Netherlands. 11. Manchester Academic Health Sciences Centre, Royal Manchester Children's Hospital, Manchester, UK.
Abstract
Objective: To provide outcome data concerning pregnancies exposed to the Interleukin-1 (IL-1) inhibitors prior to conception in both men and women, during pregnancy and breast feeding. Methods: Retrospective data were collected from members of the International Society for Systemic Autoinflammatory diseases and collated in a single centre. A uniform data collection sheet was used to obtain standardized data including maternal age and diagnosis, type, duration of and response to IL-1 blockade, pregnancy duration, delivery, mode of feeding and neonatal development. Results: There were 31 maternal-exposed pregnancies from seven countries and we report the first data on paternal exposure: six to anakinra and five to canakinumab, with no negative outcomes. We also report the first data on canakinumab-exposed pregnancies: eight pregnancies that resulted in the delivery of seven healthy infants of normal gestational age and birthweight. There were 23 anakinra-exposed pregnancies resulting in the birth of 21 healthy infants, and one baby with unilateral renal agenesis and ectopic neurohypophysis. There were two first trimester miscarriages affecting a mother with active disease. There were no serious neonatal infections. Fourteen infants were breast fed with no complications. There were no reports of developmental delay, with follow-up of up to 10 years (median 18 months). Conclusion: This series substantially increases the published experience of IL-1 blockade and reproduction including the first data on canakinumab and on paternal exposure to these agents. Data are generally reassuring, although the case of renal agenesis is the second reported in an anakinra-exposed pregnancy.
Objective: To provide outcome data concerning pregnancies exposed to the Interleukin-1 (IL-1) inhibitors prior to conception in both men and women, during pregnancy and breast feeding. Methods: Retrospective data were collected from members of the International Society for Systemic Autoinflammatory diseases and collated in a single centre. A uniform data collection sheet was used to obtain standardized data including maternal age and diagnosis, type, duration of and response to IL-1 blockade, pregnancy duration, delivery, mode of feeding and neonatal development. Results: There were 31 maternal-exposed pregnancies from seven countries and we report the first data on paternal exposure: six to anakinra and five to canakinumab, with no negative outcomes. We also report the first data on canakinumab-exposed pregnancies: eight pregnancies that resulted in the delivery of seven healthy infants of normal gestational age and birthweight. There were 23 anakinra-exposed pregnancies resulting in the birth of 21 healthy infants, and one baby with unilateral renal agenesis and ectopic neurohypophysis. There were two first trimester miscarriages affecting a mother with active disease. There were no serious neonatal infections. Fourteen infants were breast fed with no complications. There were no reports of developmental delay, with follow-up of up to 10 years (median 18 months). Conclusion: This series substantially increases the published experience of IL-1 blockade and reproduction including the first data on canakinumab and on paternal exposure to these agents. Data are generally reassuring, although the case of renal agenesis is the second reported in an anakinra-exposed pregnancy.
Authors: Helen J Lachmann; Isabelle Kone-Paut; Jasmin B Kuemmerle-Deschner; Kieron S Leslie; Eric Hachulla; Pierre Quartier; Xavier Gitton; Albert Widmer; Neha Patel; Philip N Hawkins Journal: N Engl J Med Date: 2009-06-04 Impact factor: 91.245
Authors: Zenas Chang; Catherine Y Spong; Adriana A Jesus; Michael A Davis; Nicole Plass; Deborah L Stone; Dawn Chapelle; Patrycja Hoffmann; Daniel L Kastner; Karyl Barron; Raphaela T Goldbach-Mansky; Pamela Stratton Journal: Arthritis Rheumatol Date: 2014-11 Impact factor: 10.995
Authors: Micol Romano; Z Serap Arici; David Piskin; Sara Alehashemi; Daniel Aletaha; Karyl Barron; Susanne Benseler; Roberta A Berard; Lori Broderick; Fatma Dedeoglu; Michelle Diebold; Karen Durrant; Polly Ferguson; Dirk Foell; Jonathan S Hausmann; Olcay Y Jones; Daniel Kastner; Helen J Lachmann; Ronald M Laxer; Dorelia Rivera; Nicola Ruperto; Anna Simon; Marinka Twilt; Joost Frenkel; Hal M Hoffman; Adriana A de Jesus; Jasmin B Kuemmerle-Deschner; Seza Ozen; Marco Gattorno; Raphaela Goldbach-Mansky; Erkan Demirkaya Journal: Arthritis Rheumatol Date: 2022-05-27 Impact factor: 15.483